Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy By Ogkologos - September 28, 2026 6 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TAISHAN-302 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer Workforce No improvement in OS, but more grade 3 or higher AEs with atezolizumab plus SBRT among patients with inoperable early-stage NSCLC ESMO Calls on the European Commission to Fund Cancer Research and Allocate Funding of at Least €200 Billion to the 10th EU Framework Programme... MOST POPULAR Survivor’s Lucky Chance Encounter with Her Old Surgeon Leads to an... August 6, 2021 The rise of the ‘long-waiter’ – why cancer waiting times are... November 10, 2022 Toddler Hailed A Hero After He Saved His Family From Fire... January 28, 2022 Poziotinib Shows Promise in EGFR and HER2 Exon 20 Mutated Non-Small... March 2, 2021 Load more HOT NEWS FDA Grants Accelerated Approval to Sotorasib for KRAS G12C-mutated NSCLC Biomarkers of Pro-Inflammatory Response May Identifiy Cancer Patients at Risk of... FDA Approves Cemiplimab-rwlc for Locally Advanced and Metastatic Basal Cell Carcinoma How “the most advanced machine learning approach” is finding new cancer-causing...
